Amicus Therapeutics Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.

Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics, Inc.

Country	United States
Founded	2002
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	517
CEO	Bradley Campbell

Contact Details

Address: 47 Hulfish Street Princeton, Delaware 08542 United States
Phone	609 662 2000
Website	amicusrx.com

Stock Details

Ticker Symbol	0HF9
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US03152W1099
SIC Code	2836

Key Executives

Name	Position
Bradley Campbell	Chief Executive Officer
Simon Nicolas Harford	Chief Financial Officer
Andrew Faughnan	Head of Investor Relations